Patents Examined by James S. Ketter
  • Patent number: 10287590
    Abstract: The invention provides methods for introducing co-varying paired nucleic acids into a vector such under separate transcriptional control. An oligonucleotide is synthesized including the paired nucleic acids. The oligonucleotide is then assembled with a spacer nucleic acid encoding a promoter. After assembly the spacer nucleic acid is to one side of the oligonucleotide encoding the paired segments. However, on circularization of the assembled nucleic acid and cleavage between the DNA segments the spacer oligonucleotide and its components now occur between the paired segments. The resulting nucleic acid can now be cloned into a vector with a single step, such that each of the paired nucleic acid segments is linked to its own promoter. The present method can readily be extended to library screening without proportionately increasing the effort.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: May 14, 2019
    Assignee: DNA2.0, INC.
    Inventors: Jeremy Minshull, Sridhar Govindrajan, Kedar Patel
  • Patent number: 10273520
    Abstract: The present invention is concerned with a method of production of authentic human epidermal growth factor (EGF) and hyper-production of authentic basic fibroblast growth factor (bFGF) without any modification at either C- or N-terminal of the bFGF.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: April 30, 2019
    Inventor: Wan Keung Raymond Wong
  • Patent number: 10220031
    Abstract: Potent modulators of RNA function can be assembled in cellulo by using the cell as a reaction vessel and a disease-causing RNA as a catalyst. When designing small molecule effectors of function, a balance between permeability and potency must be struck. Low molecular weight compounds are more permeable while higher molecular weight compounds are more potent. The advantages of both types of compounds could be synergized if low molecular weight molecules could be transformed into potent, multivalent ligands via a reaction catalyzed by binding to a target in cells expressing a genetic defect. We demonstrate that this approach is indeed viable in cellulo. Small molecule modules with precisely positioned alkyne and azide moieties bind adjacent internal loops in r(CCUG)exp, the causative agent of myotonic dystrophy type 2 (DM2), and are transformed into oligomeric, potent inhibitors of DM2 RNA dysfunction via a 1,3 Huisgen dipolar cycloaddition reaction, a variant of click chemistry.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 5, 2019
    Assignee: The Scripps Research Institute
    Inventors: Matthew D. Disney, Suzanne G. Rzuczek
  • Patent number: 10214750
    Abstract: Systems and methods are disclosed herein for use in transducing, activating, and otherwise treating cells. Cells are introduced into an inner layer of a multi-layered stack that defines at least one flow chamber and a plurality of cell entrainment regions. Vertical flow through the stack entrains the cells in the cell entrainment regions along with genetic information introduction agents or other additives, before the cells are washed using a reverse vertical flow and are collected from the device.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 26, 2019
    Assignee: The Charles Stark Draper Laboratory, Inc.
    Inventors: Jeffrey T. Borenstein, Joseph L. Charest, Christopher M. DiBiasio, Dorit Berlin, Jenna Balestrini, Jose A. Santos, Vishal Tandon
  • Patent number: 10202641
    Abstract: Disclosed herein are methods and systems for correcting errors in sample amplification, including the errors occurred in determining the number of targets in samples. In some embodiments, the method comprises: stochastically barcoding a plurality of targets in the samples using oligonucleotides comprising stochastic barcodes to generate stochastically barcoded targets; contacting one or more defined barcoded primers with each of the one or more samples; and determining an amplification noise.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: February 12, 2019
    Assignee: Cellular Research, Inc.
    Inventor: Eleen Shum
  • Patent number: 10196708
    Abstract: This disclosure provides engineered microbes modified such that the surface of the microbe contains one or more rare earth element (REE) binding ligands, as well as methods of use thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 5, 2019
    Assignee: Lawrence Livermore National Security, LLC
    Inventors: Yongqin Jiao, Dan Mcfarland Park, Mimi Cho Yung, David W. Reed
  • Patent number: 10184135
    Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: January 22, 2019
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Doreen Jahn, Antje Danielczyk
  • Patent number: 10184933
    Abstract: HIV-1's ability to enter a transcriptionally dormant state and establish a reservoir of latently infected cells is considered the major barrier to eradicating the virus from infected patients. Stochastic noise (i.e. fluctuations) in an HIV-1 transcriptional positive-feedback loop is one mechanism that enables HIV-1 to establish latency. Here, Applicants demonstrate that small-molecule modulation of noise in HIV-1 gene expression radically perturbs HIV-1 latency.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: January 22, 2019
    Assignee: The J. David Gladstone Industries
    Inventors: Leor Weinberger, Roy Dar
  • Patent number: 10180438
    Abstract: A method is described to obtain a class of embryos having a higher implantation potential than from morphology selection alone by selecting from a plurality of embryos, obtained by fertilizing the plurality of oocytes, a class of embryos having a high implantation potential. The selection is determined from a level of granulocyte-colony stimulating factor (G-CSF) present in the follicular fluid (FF) of each oocyte in the plurality of oocytes.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: January 15, 2019
    Assignee: FEMALON S.P.R.L.
    Inventors: Nathalie Ledee, Marie-Pierre Piccinni
  • Patent number: 10179934
    Abstract: Disclosed is a high-throughput detection method for a DNA synthesis product. According to the method of the present invention, a high-throughput sequencing technology is applied to detection of a DNA chip synthesis product through a mixed library construction strategy, so that costs of product detection and accurate product screening are reduced.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: January 15, 2019
    Assignee: BGI Shenzhen
    Inventors: Kang Kang, Shihong Chen, Yue Shen, Yun Wang, Xun Xu
  • Patent number: 10174361
    Abstract: The present invention is directed to methods of isolating particles, such as nucleic acid-containing particles or microvesicles, from a biological sample and extracting nucleic acids therefrom, wherein the biological sample is cerebrospinal fluid. The present invention further provides methods for aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker associated with a disease or medical condition thereof.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: January 8, 2019
    Assignee: Exosome Diagnostics, Inc.
    Inventors: Johan Karl Olov Skog, Leileata Russo
  • Patent number: 10174307
    Abstract: The invention provides mutant Escherichia coli cells that contain one or more mutations in one or more of the rpoB, hns/tdk, cor A, ygaZ, iap, metL, ygeW, and pyrE/rph genes (exemplified in Table 2A and 2B), which confer on the mutant in M9-glucose minimal media the phenotype of increased level of growth and/or increased glucose uptake rate and/or increased acetate production rate and/or increased biomass yield, compared to a control E. coli (such as wild type E. coli) that lacks the one or more mutations in the one or more genes.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: January 8, 2019
    Assignee: The Regents of the University of California
    Inventors: Adam M. Feist, Bernhard O. Palsson
  • Patent number: 10155951
    Abstract: The invention described herein relates to methods, systems, compositions and cells to provide one or more toxic non-native proteins in a cell, wherein the one or more toxic non-native proteins are contained in at least one empty microcompartment within the cell.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: December 18, 2018
    Assignee: Lawrence Livermore National Security, LLC
    Inventors: Mimi Cho Yung, Feliza A. Bourguet, Timothy S. Carpenter, Matthew A. Coleman
  • Patent number: 10140418
    Abstract: A system (100) for classifying a biological test sample, including a database (112) populated with reference expression data. The reference expression data includes expression levels of a plurality of molecules (polynucleotides or polypeptides), including a set of marker molecules, in a plurality of reference samples. Each reference sample has a pre-assigned value for each of one or more clinically significant variables. The system includes at least one processor (110) and at least one storage medium containing program instructions for execution by said processor (110). The program instructions cause the processor to accept (122) input expression data including a test vector of expression levels of the marker molecules in the biological test sample; and pass the input expression data to one or more analysis programs (130a, 130b, 135).
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 27, 2018
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Ryan L. Van Laar
  • Patent number: 10131870
    Abstract: This disclosure describes techniques for creating stable, targeted mutations in Spirulina (Athrospiria) and Spirulina having stable, targeted mutations.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: November 20, 2018
    Assignee: LUMEN BIOSCIENCE, INC.
    Inventors: Ryo Takeuchi, James Roberts
  • Patent number: 10131914
    Abstract: The present disclosure relates to an expression cassette including an rrnA promoter derived from Vibrio natriegens for enhancing the growth rate of Escherichia coli and recombinant Escherichia coli, into which the expression cassette is introduced. More particularly, the present disclosure relates to an expression cassette including the Vibrio natriegens-derived rrnA promoter for enhancing the growth rate of Escherichia coli by introduction thereof into an rrn operon promoter region of Escherichia coli.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: November 20, 2018
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ji Hyun Kim, Ki Tae Kim, Soon Kyeong Kwon
  • Patent number: 10130288
    Abstract: Disclosed herein are sensors with a layer of dehydrated modified basement membrane preparation formed thereon. The basement membrane has been modified before dehydration of remove low molecular weight components. In some embodiments, the basement membrane is crosslinked. Methods of making and using the products also are disclosed.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: November 20, 2018
    Assignee: Cell and Molecular Tissue Engineering, LLC
    Inventors: Ulrike W. Klueh, Donald L. Kreutzer
  • Patent number: 10125361
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 13, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 10119975
    Abstract: Systems, methods, libraries, kits, and computer software tools are provided for designing and producing engineered cells. Such engineered cells can be used for cell state quantification, such as genome, transcriptome and/or proteome quantification. In one aspect, an engineered cell having a plurality of artificially designed oligonucleotides introduced into the genome of the cell is provided. The oligonucleotides are each located in proximity of a gene of interest encoding a protein of interest, and are different from one another. The oligonucleotides can each encode a unique peptide tag for each protein of interest, wherein each peptide tag has a unique quantitatively measurable value such as mass-to-charge ratio which can be quantified by a mass spectrometer. The engineered cell is capable of expressing a plurality of proteins of interest each fused to its corresponding unique peptide tag, wherein each peptide tag is capable of being released therefrom.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: November 6, 2018
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Reshma Shetty, Thomas F. Knight, Jr., Randall D. Rettberg
  • Patent number: 10106802
    Abstract: The present invention relates to the application of isolated promoters and synthetic constructs for efficient production of genetically modified cells in a species selected from the Pucciniomycotina and Ustilaginomycotina subphyla, in particular, species selected from the Rhodosporidium, Rhodotourla, Sporobolomyces or Pseudozyma genus.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 23, 2018
    Assignee: TEMASEK LIFE SCIENCES LABORATORY LIMITED
    Inventors: Hsin I. Cheng, Ni Peng, Lianghui Ji